Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer

Balalaeva, Irina V.; Krylova, Lubov V.; Karpova, Maria A.; Shulga, A. A.; Коновалова, Е. В.; Guryev, Evgenii L.; Deyev, Sergey M.

doi:10.1134/s1607672922340038

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio between agents' concentrations was maintained equal (1:250), which corresponds to the IC50 ratio (Figure 2). The calculated combination index was 0.07, indicating a significant synergistic effect of the agents [7]. The half-maximal decrease in the viability of the SK-BR-3 cell culture was observed at concentrations of the toxin and photosensitizer that are virtually non-toxic to cells when the agents are used separately.…”

Section: Resultsmentioning

confidence: 96%

See 1 more Smart Citation

Synergistic Effect of the Combination of the Recombinant Toxin DARPin-LoPE and PDT against HER2-Positive Breast Cancer In Vitro

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 96%

“…Relative viability of SK-BR-3 cell after the treatment with DARPin-LoPE and PDT (20 J/cm 2 )and their combined effects. Adapted with permission from Ref [7]…”

mentioning

confidence: 99%

Synergistic Effect of the Combination of the Recombinant Toxin DARPin-LoPE and PDT against HER2-Positive Breast Cancer In Vitro

et al. 2023

View full text Add to dashboard Cite

show abstract

Non-Immunoglobulin Synthetic Binding Proteins for Oncology

David,

Pestov,

Korneenko

et al. 2023

Biochemistry Moscow

View full text Add to dashboard Cite

Extensive application of technologies like phage display in screening peptide and protein combinatorial libraries has not only facilitated creation of new recombinant antibodies but has also significantly enriched repertoire of the protein binders that have polypeptide scaffolds without homology to immunoglobulins. These innovative synthetic binding protein (SBP) platforms have grown in number and now encompass monobodies/adnectins, DARPins, lipocalins/anticalins, and a variety of miniproteins such as affibodies and knottins, among others. They serve as versatile modules for developing complex affinity tools that hold promise in both diagnostic and therapeutic settings. An optimal scaffold typically has low molecular weight, minimal immunogenicity, and demonstrates resistance against various challenging conditions, including proteolysis – making it potentially suitable for peroral administration. Retaining functionality under reducing intracellular milieu is also advantageous. However, paramount to its functionality is the scaffold’s ability to tolerate mutations across numerous positions, allowing for the formation of a sufficiently large target binding region. This is achieved through the library construction, screening, and subsequent expression in an appropriate system. Scaffolds that exhibit high thermodynamic stability are especially coveted by the developers of new SBPs. These are steadily making their way into clinical settings, notably as antagonists of oncoproteins in signaling pathways. This review surveys the diverse landscape of SBPs, placing particular emphasis on the inhibitors targeting the oncoprotein KRAS, and highlights groundbreaking opportunities for SBPs in oncology.

show abstract

Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer

Cited by 2 publications

References 17 publications

Synergistic Effect of the Combination of the Recombinant Toxin DARPin-LoPE and PDT against HER2-Positive Breast Cancer In Vitro

Synergistic Effect of the Combination of the Recombinant Toxin DARPin-LoPE and PDT against HER2-Positive Breast Cancer In Vitro

Non-Immunoglobulin Synthetic Binding Proteins for Oncology

Contact Info

Product

Resources

About